Zellweger diseases refer to a group of rare genetic disorders that affect the function of the cells' organelles called peroxisomes. The word "Zellweger" is spelled /ˈzɛlwɛɡər/ in IPA phonetic transcription. It's named after Dr. Hans Zellweger, who first described the condition in 1964. The correct spelling of the disease is essential to help medical professionals diagnose and treat affected individuals accurately. Zellweger diseases can cause various symptoms such as developmental delay, vision loss, liver dysfunction, and muscle weakness. Treatment often focuses on managing symptoms and providing supportive care.
Zellweger diseases, also known as Zellweger spectrum disorders (ZSDs), are a group of rare and severe genetic disorders that belong to a larger category known as peroxisomal biogenesis disorders (PBDs). These disorders are inherited in an autosomal recessive manner, meaning both copies of the gene associated with Zellweger diseases need to be mutated for the illness to occur.
Zellweger diseases primarily affect the peroxisomes, which are membrane-bound organelles responsible for various metabolic functions in cells. Due to genetic mutations, individuals with Zellweger diseases have impaired biogenesis of peroxisomes, resulting in their absence or malfunction. This disruption leads to the accumulation of toxic substances and the inability to break down certain fatty acids and other compounds.
The symptoms of Zellweger diseases typically manifest early in infancy and may include poor muscle tone, developmental delays, neurological abnormalities, liver dysfunction, and distinctive facial features such as a high forehead, large fontanelle, and wide-set eyes. Affected individuals often experience life-threatening complications and have a limited life expectancy.
Unfortunately, there is currently no cure for Zellweger diseases. Treatment mainly focuses on managing the symptoms and providing supportive care to affected individuals. This may involve a multidisciplinary approach involving various medical specialists, such as neurologists, hepatologists, and genetic counselors, to address the complex needs of patients.
Overall, Zellweger diseases are a group of rare genetic disorders characterized by impaired peroxisomal function, leading to severe metabolic abnormalities and significant health challenges for affected individuals.
The term "Zellweger diseases" derives from the name of the Swiss pediatrician, Hans Zellweger. In the 1960s, Zellweger, along with his colleagues, described a group of rare genetic disorders characterized by impaired peroxisome function. These disorders were later collectively termed "Zellweger syndrome" in honor of Hans Zellweger's contributions to their understanding. Over time, further research revealed a spectrum of similar disorders, and the term "Zellweger diseases" began to be used to encompass the broader category.